HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 250 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR Patients with Early Stage NSCLC Have a Higher TMB in Comparison... October 9, 2020 Beating the Heat with Beets July 31, 2020 New on NCI’s Websites for September 2022 September 21, 2022 Study Shows That Fast-Mimicking Diets Are Safe and Effective for Patients... July 20, 2020 Load more HOT NEWS Green Beret With Lung Cancer Surprised With Hundreds Of ‘Thank You’... The Opioid Epidemic and Cancer Pain Management: A Conversation with Dr.... FDA Approves Relugolix for Advanced Prostate Cancer NCI Launches New Resource for Specimens and Data from Cancer Clinical...
